What does an elevated fasting insulin and C‑peptide indicate and how should it be managed?

Elevated Fasting Insulin and C-Peptide: Diagnostic Significance and Management

Elevated fasting insulin and C-peptide indicate endogenous hyperinsulinism, which requires immediate evaluation to distinguish between insulin resistance syndromes (metabolic syndrome, type 2 diabetes) and dangerous causes of hypoglycemia (insulinoma, nesidioblastosis, oral hypoglycemic agents). The critical first step is determining whether the patient has hypoglycemia or hyperglycemia at the time of these elevated values.

Algorithmic Approach Based on Clinical Context

If Patient Has Hypoglycemia (Glucose <55 mg/dL or 3.0 mmol/L):

This is a medical emergency requiring urgent evaluation for endogenous hyperinsulinemic hypoglycemia 1.

Diagnostic Criteria for Endogenous Hyperinsulinism During Hypoglycemia:

• Glucose <55 mg/dL (3.0 mmol/L) with symptoms 1
• Insulin ≥3.0 µU/mL (18 pmol/L) 1, 2
• C-peptide ≥0.6 ng/mL (0.2 nmol/L) 1, 2
• Proinsulin ≥5.0 pmol/L 1
• β-hydroxybutyrate ≤2.7 mmol/L (suppressed ketogenesis confirms insulin-mediated hypoglycemia) 1, 2

Critical caveat: C-peptide has superior diagnostic performance to insulin, with nearly 100% sensitivity and specificity at the 0.6 ng/mL threshold for hypoglycemia ≤45 mg/dL 2. Recent data suggests C-peptide ≥0.30 nmol/L with glucose <2.3 mmol/L (41 mg/dL) provides optimal diagnostic accuracy (96% sensitivity, 100% specificity) 3.

Differential Diagnosis of Endogenous Hyperinsulinemic Hypoglycemia:

1. Screen for oral hypoglycemic agents (sulfonylureas, meglitinides) - must be negative 1
2. Measure insulin antibodies - if positive, suggests exogenous insulin use or insulin autoimmune syndrome 1
3. If both negative: Likely insulinoma, nesidioblastosis (NIPHS), or post-gastric bypass hypoglycemia 1

Localization and Management:

• Proceed to tumor localization with multiphasic CT/MRI (70-85% sensitivity), endoscopic ultrasound (>90% sensitivity), or selective arterial calcium stimulation 1, 4
• Surgical resection is definitive treatment for insulinoma (90% are benign and curable) 4
• Medical management with diazoxide, octreotide, or frequent feedings for non-surgical candidates 1

If Patient Has Normal or Elevated Glucose (No Hypoglycemia):

Elevated fasting insulin and C-peptide in the absence of hypoglycemia indicate insulin resistance, most commonly associated with metabolic syndrome, prediabetes, or type 2 diabetes.

Interpretation in Hyperglycemic/Euglycemic States:

High C-peptide with elevated glucose signals insulin resistance and hyperinsulinemia, which carries significant cardiovascular risk 5, 6, 7. This pattern is the hallmark of metabolic syndrome and early type 2 diabetes.

Key Clinical Correlations:

• Cardiovascular risk: Elevated fasting C-peptide independently predicts cardiovascular mortality (HR 1.60) and all-cause mortality (HR 1.72) in non-diabetic adults 6
• In type 2 diabetes: High C-peptide at diagnosis predicts cancer mortality (HR 1.51) and overall mortality (HR 1.33) 7
• Metabolic associations: Correlates with triglycerides, low HDL, BMI, intra-abdominal fat, and hepatic steatosis 5, 8

Management Strategy:

Focus on reducing insulin resistance rather than adding more insulin 9, 10:

1. Lifestyle modification: Weight loss, exercise, dietary changes targeting visceral adiposity

2. Pharmacotherapy prioritizing insulin sensitizers:

   • Metformin as first-line
   • GLP-1 receptor agonists or SGLT2 inhibitors for cardiovascular protection (especially if C-peptide markedly elevated)
   • Avoid or minimize exogenous insulin when C-peptide remains elevated, as this worsens hyperinsulinemia and cardiovascular risk 10

3. C-peptide/glucose ratio (CGR) for therapeutic decisions 9:

   • High CGR: Indicates insulin hypersecretion → prioritize cardiovascular risk reduction with GLP-1 agonists/SGLT2 inhibitors
   • Low CGR: Indicates insulin deficiency → insulin therapy appropriate
   • Intermediate CGR: Consider de-escalation if mild diabetes

Critical Pitfalls to Avoid:

1. Never assume elevated insulin/C-peptide means "good beta-cell function" in the setting of hyperglycemia - it signals pathologic insulin resistance requiring aggressive intervention 9, 7

2. Do not miss hypoglycemia: If patient has any symptoms suggesting hypoglycemia (confusion, sweating, palpitations), document glucose during symptoms with simultaneous insulin and C-peptide 1

3. Hemolyzed samples underestimate insulin but not C-peptide - C-peptide is more reliable 3

4. Stop PPIs 10-14 days before testing if evaluating for gastrinoma (raises gastrin and C-peptide) 11

5. In type 2 diabetes misdiagnosed as type 1: Measuring C-peptide can prevent decades of inappropriate insulin therapy 10. Consider testing if diagnosis unclear, especially in adults with preserved BMI 12